
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen's stock has experienced a significant rally, with shares rising approximately 35% since the beginning of the third quarter of 2025, in contrast to a 40% increase in the broader biopharmaceutical index. The company is strategically positioned with key new product launches such as Leqembi, Skyclarys, and Zurzuvae, which have outperformed expectations and may drive near-term earnings growth. Additionally, Biogen’s expanding neuroscience portfolio and strong cash flow support continued investment in high-risk research and development, further enhancing its market position and potential for revenue growth.
Bears say
Biogen is projected to experience a significant decline in revenue, with estimates dropping from $9.8 billion in 2025 to $5.1 billion by 2040, falling below consensus expectations and reflecting a largely flat revenue compound annual growth rate (CAGR) from 2026 to 2030. The company's major dependency on its multiple sclerosis (MS) franchise, which is facing intensifying competition and the impending launch of biosimilars, particularly threatens its revenue stream, as evidenced by guidance indicating a 5-8% decrease in global MS revenues in the latter half of 2025. Additionally, declining royalties from key collaborations, particularly with Roche, along with anticipated challenges for its newer products and the overall EBITDA CAGR turning negative at (4%) from 2026 to 2030, further contribute to the negative outlook on Biogen's financial trajectory.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares